A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

Summary

The purpose of this study is to provide safety data and demonstrate lot consistency with the PG4 vaccine by evaluating the immunogenicity of 3 different lots of this vaccine. This study will compare a new pneumococcal vaccine with the vaccine currently in use to see if they are similarly safe. It will also compare three batches of the new vaccine to make sure they work the same way. Blood samples will be taken to measure how the body responds to the vaccines. The study will be conducted in the United States. Participants will be assigned to 1 of 4 groups.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Pneumococcal Disease

Eligibility basics and study details

Study type

Interventional

Phase

Phase 3

Ages

18 to 49 years

Sex

All

Healthy volunteers

Accepted

Sponsor

Pfizer

Last updated on ClinicalTrials.gov

October 14, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites